1-cyclohexyl-4-(4-fluorophenyl)-5-[[2-[N-(3-morpholino)propyl]amino]pyrimidin-4-yl]imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-cyclohexyl-4-(4-fluorophenyl)-5-[[2-[N-(3-morpholino)propyl]amino]pyrimidin-4-yl]imidazole
• 英文别名: 4-[3-cyclohexyl-5-(4-fluorophenyl)imidazol-4-yl]-N-(3-morpholin-4-ylpropyl)pyrimidin-2-amine
• 化学式: C₂₆H₃₃FN₆O
• 分子量: 464.586
• InChiKey: IMGLMZQSQAJQDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  68.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N-(3-氨丙基)吗啉 、 2-[1-methyl-5-(phenylsulfonyl)-1H-indol-3-yl]ethanamine hydrochloride 以 四氢呋喃 为溶剂， 反应 18.0h， 以26%的产率得到1-cyclohexyl-4-(4-fluorophenyl)-5-[[2-[N-(3-morpholino)propyl]amino]pyrimidin-4-yl]imidazole
  参考文献：
  名称：

  compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses

  摘要：

  1,4,5-取代咪唑化合物，其中一个取代基可以是取代嘧啶、吡啶并[2,3-d]二嗪或1,2,4-三嗪。这些化合物及其药物组合物用于通过抑制IL-1（白细胞介素-1）、IL-8（白细胞介素-8）和TNF（肿瘤坏死因子）的产生来治疗细胞因子介导的疾病。

  公开号：

  US06335340B1

文献信息

• Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
  申请人：SmithKline Beecham Corporation

  公开号：US20020198206A1

  公开（公告）日：2002-12-26

  Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.

  小说1,4,5-取代咪唑化合物及其用于治疗作为细胞因子抑制剂的组合物。
• NOVEL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES
  申请人：THE UNIVERSITY OF MELBOURNE

  公开号：US20220002269A1

  公开（公告）日：2022-01-06

  The present invention relates to new compounds that are useful in the prevention or treatment of respiratory diseases, such as asthma, acute and chronic inflammatory conditions, and fibrotic diseases or conditions in which fibrosis contributes to the pathology of the condition. The invention also relates to the preparation of the compounds, and to compositions including the compounds. The present invention also relates to the use of the compounds, as well as compositions including the compounds, in treating or preventing respiratory diseases, acute and chronic inflammatory conditions, and fibrotic diseases or conditions in which fibrosis contributes to the pathology of the condition.
• US6335340B1
  申请人：——

  公开号：US6335340B1

  公开（公告）日：2002-01-01
• US6730683B2
  申请人：——

  公开号：US6730683B2

  公开（公告）日：2004-05-04